21 CFR 820.250
Sampling plans
- Inspections citing it: 504
- Of those classified, ended OAI: 26%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 820.250(b)
- 330 · Sampling plans
- 820.250(a)
- 174 · Statistical techniques - Lack of or inadequate procedures
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- Marson Medical, Inc.United States · Jan 16, 2026
- Nuclein LLCUnited States · Jan 13, 2026
- Creative Foam Corporation - BremenUnited States · Nov 24, 2025
- Turbett Surgical, Inc.United States · Nov 6, 2025
- Keystone IndustriesUnited States · Sep 30, 2025
- Jabil Tuttlingen Manufacturing GMBHGermany · Sep 18, 2025
- MACLEAN-FOGGUnited States · May 22, 2025
- R-Med IncUnited States · Apr 23, 2025
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR